Fig. 2: miR-1304 inhibition affects viability of a range of NB cell lines and decreases sensitivity of ALK mutant NB cells to brigatinib and ceritinib.

A–D SH-SY5Y cell viability and ALK TKI ED₅₀s, 5 days post transfection of the indicated miRNA inhibitors followed by 72 h exposure to either brigatinib (A, B) or ceritinib (C, D). All results are normalized to the viability of the untreated (DMSO) control for each miRNA inhibitor treatment conducted. ED₅₀s were calculated using a non-linear regression curve. Results are shown as means ± SEM from three biological replicates each conducted with technical triplicates. Statistical comparison was conducted using a two-tailed Student’s t test of the means of three biological replicates in B, D; B *p = 0.037, D *p = 0.019. E, F Cell viability 72 h following transfection with E the miR-1304-5p inhibitor or F a miR-1305-5p mimic in a panel of 17 NB cell lines. ALK WT cells are highlighted in blue = CHP-134, GIMEN, NBL-S, NGP. The other cell lines have activating ALK mutations, as specified in Supplementary Table 2. Data points (n = 6) shown in the graphs on the left are from six technical replicates (independent transfections). Statistics were conducted using the means ± SEM from 17 different cell lines (biological replicates) with a two-tailed Student’s t test; ****p < 10⁻¹⁵. Source data are provided in a Source Data file.